Rethinking clinical trial endpoints for evaluating serially delivered 'strategic radiotherapy' in oligometastatic or oligoprogressive metastatic disease

Jee Suk Chang; Florence T H Wu; Heejoo Ko; Emma M Dunne; Sarah Baker; Mitchell Liu

doi:10.1016/j.canlet.2025.218106

1. Journal Papers
Dept. of Radiation Oncology (방사선종양학교실)
1. College of Medicine (의과대학)

0 8

Cited 0 times in

Rethinking clinical trial endpoints for evaluating serially delivered 'strategic radiotherapy' in oligometastatic or oligoprogressive metastatic disease

Authors: Jee Suk Chang ; Florence T H Wu ; Heejoo Ko ; Emma M Dunne ; Sarah Baker ; Mitchell Liu

Citation: CANCER LETTERS, Vol.635 : 218106, 2025-12

Journal Title: CANCER LETTERS

ISSN: 0304-3835

Issue Date: 2025-12

Full Text: https://www.sciencedirect.com/science/article/pii/S0304383525006780

DOI: 10.1016/j.canlet.2025.218106

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

Yonsei Authors: Chang, Jee Suk(장지석) https://orcid.org/0000-0001-7685-3382

URI: https://ir.ymlib.yonsei.ac.kr/handle/22282913/209750

사서에게 알리기

Show full item record Find it @ YMLIB

YUHSpace: Rethinking clinical trial endpoints for evaluating serially delivered 'strategic radiotherapy' in oligometastatic or oligoprogressive metastatic disease

YUHSpace

BROWSE

Browse

Links